These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35017325)

  • 21. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
    JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of edaravone in preventing contrast-induced nephropathy in high-risk patients undergoing coronary angiography: A randomized, double-blind trial.
    Esmailnejad A; Zununi Vahed S; Hejazian SM; Aslanabadi N; Lotfollahhi Gharakhanlu H; Saraei M; Ahmadzadehpournaky A; Ardalan K; Ardalan M; Ghaffari Bavil S
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1228. PubMed ID: 38956898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
    Hafiz AM; Jan MF; Mori N; Shaikh F; Wallach J; Bajwa T; Allaqaband S
    Catheter Cardiovasc Interv; 2012 May; 79(6):929-37. PubMed ID: 21542114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
    Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
    Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy.
    Baskurt M; Okcun B; Abaci O; Dogan GM; Kilickesmez K; Ozkan AA; Ersanli M; Gurmen T
    Eur J Clin Invest; 2009 Sep; 39(9):793-9. PubMed ID: 19500141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
    Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
    J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT).
    ACT Investigators
    Circulation; 2011 Sep; 124(11):1250-9. PubMed ID: 21859972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
    J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
    J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
    Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
    Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.